advanced solid tumors

RMC-6236 is a RAS(ON)MULTI inhibitor with anticancer activity and is used in the study of advanced malignant solid tumors and colorectal cancer.

TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.

AC 7739 is a microtubule protein binding agent with anticancer and antitumor activity that inhibits advanced solid tumors and in situ transplanted tumors.

IMMH 010 maleate (YPD-30 maleate) is an orally available programmed cell death ligand 1 inhibitor with potential antitumor activity for the study of neurological disorders and advanced malignant solid tumors.

CEP-40125 (RXDX-107) is a DNA alkylating agent for the study of advanced solid tumors.

Rabusertib (IC-83) is an inhibitor of the cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiating activity. Rabusertib has been used in trials studying the treatment of Cancer, Solid Tumors, Advanced Cancer, Pancreatic Neoplasms, and Non-Small Cell Lung Cancer.

PHA-793887 has been used in trials studying the treatment of Advanced/Metastatic Solid Tumors.

Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting glucocorticoid-induced TNFR-associated protein (GITR). Ragifilimab can be used in the study of advanced or metastatic solid tumors.

Varlilumab (CDX-1127) is a novel human IgG1 anti-CD27 monoclonal antibody. Varlilumab has antitumor activity and can be used to study advanced solid tumors.

Betifisolimab (MSB-2311), a humanized monoclonal antibody targeting the immunosuppressive ligand PD-L1, shows promise for research in advanced solid tumors and hematological malignancies [1].

Tulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor.Tulmimetostat has antitumor activity and is used in the study of ovarian cancer and advanced solid tumors.

IACS-9439 is a potent, selective, and orally active inhibitor of CSF1R, exhibiting a K(i) of 1 nM. It is applicable in the research of advanced solid tumors [1].

Carbendazim (Mercarzole) is a broad-spectrum benzimidazole antifungal with potential antimitotic and antineoplastic activities. Although the exact mechanism of action is unclear, carbendazim appears to binds to an unspecified site on tubulin and suppresses microtubule assembly dynamic. This results in cell cycle arrest at the G2/M phase and an induction of apoptosis.

Birabresib dihydrate was initially developed by Mitsubishi Tanabe Pharma Corporation, but then was licensed by OncoEthix, privately held biotechnology company. OTX015 is a selective bromodomains: BRD2, BRD3, and BRD4 inhibitor and inhibits their binding to AcH4. Bromodomains have an important role in the targeting of chromatin-modifying enzymes to specific sites, including methyltransferases, HATs and transcription factors and regulate diverse biological processes from cell proliferation and differentiation to energy homeostasis and neurological processes. OTX015 has potent antiproliferative activity accompanied by c-MYC down-regulation in several tumor types, and has demonstrated synergism with the mTOR inhibitor everolimus in different models. Oral administration of OTX-015 markedly inhibited tumor growth and reduced tumor volume. OTX015 is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors such as Triple Negative Breast ......

Trotabresib (CC-90010) is an orally active inhibitor of BET and can be used in studies about advanced solid tumors.

BT1718 is a bicyclic peptide conjugate that targets MT1-MMP, a protease overexpressed in various advanced solid tumors such as triple-negative breast cancer (TNBC) and non-small cell lung cancer [1] [2]. By exploiting MT1-MMP, BT1718 delivers its cytotoxic payload, Mertansine, with a strong affinity characterized by a dissociation constant (K D) of 3 nM.

Tisotumab vedotin is an antibody-drug conjugate (ADC) that specifically targets tissue factor (TF). This compound combines a fully human monoclonal antibody directed against TF (TF-011) with the cytotoxic agent Monomethyl Auristatin E (MMAE), exhibiting potent antitumor activity in the investigation of advanced or metastatic solid tumors [1].

Pimicotinib (ABSK021) is a potent CSF1R inhibitor with antitumor activity and can be used to study advanced solid tumors.

Irofulven is an agent of DNA-damaging and antitumor. It is used for the treatment of advanced solid tumors, including prostate, ovarian, and pancreatic cancers.

Opucolimab, an anti-PD-L1 recombinant human monoclonal antibody, has applications in synthesizing antibody-agent conjugates and is utilized in research targeting advanced solid tumors [1].

Lapatinib ditosylate (Lapatinib tosilate) monohydrate is a tyrosine kinase receptor inhibitor used in the therapy of advanced breast cancer and other solid tumors. Lapatinib ditosylate monohydrate therapy is associated with transient elevations in serum aminotransferase levels and rare instances of clinically apparent acute liver injury.

Devimistat (6,8-Bis(benzylthio)octanoic acid) , a lipoate analog, inhibits mitochondrial enzymes pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase, disrupts tumor cell mitochondrial metabolism. It has potential chemopreventive and antineoplastic activities, and has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Advanced Cancer, and Pancreatic Cancer, among others.

Rosmantuzumab (OMP-131R10) is a humanized monoclonal antibody against R-spondin 3 (RSPO3). Rosmantuzumab has potential antitumor activity and can be used to study advanced relapsed refractory solid tumors.

Conatumumab (AMG 655) is a monoclonal agonist antibody targeting human death receptor 5 (DR5, TRAILR2) at Kd 1 nM for long DR5 and Kd 0.8 nM for short DR5. Conatumumab induces apoptosis in a variety of tumor types through caspase activation. Conatumumab can be used to study advanced solid tumors.

GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is an orally active and potent inhibitor of type I protein arginine methyltransferases (PRMTs) with anticancer and antitumor activity, inhibiting PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8, and can be used to study advanced solid tumors.